Statin Therapy

In an observational study of participants from the MESA cohort, statin use was not associated with incident diabetes, researchers reported in The American Journal of Cardiology.

An LDL target of less than 70 mg/dL with ezetimibe plus statin therapy was associated with lower risk for subsequent events after stroke/transient ischemic attack at 5 years vs. a target between 90 mg/dL and 110 mg/dL, researchers reported.

Overall statin use among adults with chronic kidney disease is high, yet there have been only modest increases in the use of high‐intensity statins, ezetimibe and PCSK9 inhibitors, data from a prospective 2‐year study show.

Data from a meta-analysis show that a 20% improvement in CV medication adherence could reduce risk for any CV event by 8% and risk for all-cause mortality by 12% among patients with CAD, researchers reported.

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

Polypill with aspirin, atorvastatin and ramipril vs. usual care for secondary prevention in patients with MI.

Statin therapy after ischemic stroke is associated with improved survival and may be particularly beneficial in patients with a history of cancer, according to a brief report published in Stroke.

Last week, Healio reported from the European Society of Cardiology Congress. The top five stories in cardiology are on research presented at the meeting.

While statin therapy may cause a small excess of mostly mild muscle pain, most muscle symptoms reported in statin trials were not caused by the drug, according to a meta-analysis presented at the European Society of Cardiology Congress.

In older adults, a polypill containing aspirin, an ACE inhibitor and a statin within 6 months after myocardial infarction lowered the risk for major adverse CV events compared with usual care, according to results of the SECURE trial.